Navigation Links
NeurogesX to Present at UBS Global Life Sciences Conference
Date:9/17/2009

pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and develop
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at Upcoming Fall Conferences
2. NeurogesX Appoints New Board Director and Audit Committee Chairman
3. NeurogesX Reports Second Quarter 2009 Results
4. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
5. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
6. NeurogesX Added to Russell 3000 Index
7. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
8. NeurogesX to Present at Needham Life Sciences Conference
9. NeurogesX Receives European Commission Approval for Qutenza(TM)
10. NeurogesX Reports First Quarter 2009 Results
11. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2010)... ... , , ... ... ... ONTY ) today announced that it will restate its 2008 financial statements contained in its Annual Report on Form 10-K for the year ended ...
(Date:3/11/2010)... March 11 Stem Cell Assurance, ... pleased to announce the inclusion of one of the ... Ross , M.D., F.A.C.S.  Dr. Ross will officially take ... 2010 .  Stem Cell Assurance welcomes his appointment to ... provide medical and cosmetic procedures and cell banking to ...
(Date:3/11/2010)... a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered ... for Sick Children (SickKids) in Toronto, Ontario , granting Trillium exclusive worldwide ... transplantation and cancer. , ... ... , ...
(Date:3/10/2010)... plants is the most important technological innovation during ... has occurred as humans have used individuals carrying ... current issue of Nature an international ... revealed some of the secrets underlying the remarkable ... chicken has in recent years become the most ...
Breaking Biology Technology:Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 2Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 3Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 4Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 5Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 6Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 7Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 8Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 9Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 10Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 2Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 3Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 4Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3Scientific breakthrough in genetic studies of animal domestication 2
... of DxS Scorpions™ technology to test for contaminant microorganisms that reduce ... contaminant microbes can increase profitability. , ... St. Helena, ... exclusive license to use this technology in the wine industry since ...
... are like Typhoid Mary. They can spread viruses which cause ... getting sick. Scientists long thought that the mosquito didn,t care ... "There is a war going on," said Zach Adelman, assistant ... at the cellular level, between the host and invading RNA ...
... OMAHA, Neb. and HOUSTON, Dec. 2 ... Medical Products, Inc. (OTC,Bulletin Board: PWRM) today ... of,intent to acquire exclusive rights for Power3 ... diagnostic for Alzheimer,s,and Parkinson,s disease. Transgenomic ...
Other Biology Technology:ETS Laboratories Offers New Process Optimization Tools to the Fuel Ethanol Industry 2Virginia Tech researchers discover how mosquitoes avoid succumbing to viruses they transmit 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4
(Date:3/12/2010)... March 12, 2010 Keystone Symposia on Molecular ... of a $1.37 million, five-year MARC (Minority Access ... the National Institute of General Medical Sciences of ... Visible Ethnic Minority Scientists and Trainees at Keystone ... to enhance participation in biomedical research by historically ...
(Date:3/12/2010)... in the stygian depths of caves are throwing light ... evolutionary dead-ends. According to a new phylogenetic analysis of ... surface (under stones and in leaf litter) evolved independently ... life further below the surface (in caves). The research, ... published in the April issue of Cladistics . ...
(Date:3/11/2010)... the main vector of malaria have found ... act triggers two enzymes to form a network of ... this protein barrier, the researchers found, is part of ... commensal gut bacteria to grow without activating mosquito immune ... prevents the mosquito,s immune defense system from clearing ...
Breaking Biology News(10 mins):Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 2Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 3Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 4Phylogenetic analysis of Mexican cave scorpions suggests adaptation to caves is reversable 2Phylogenetic analysis of Mexican cave scorpions suggests adaptation to caves is reversable 3Barrier in mosquito midgut protects invading pathogens 2Trust in a teardrop 9687 1Trust in a teardrop 9687 2USDA grant to educate AIDS patients about food safety 9685 1USDA grant to educate AIDS patients about food safety 9685 2Nick Jonas Speaks at National Press Club in Effort to Educate Support and Inspire Kids With Diabetes 55174 1Nick Jonas Speaks at National Press Club in Effort to Educate Support and Inspire Kids With Diabetes 55174 2Nick Jonas Speaks at National Press Club in Effort to Educate Support and Inspire Kids With Diabetes 55174 3Nick Jonas Speaks at National Press Club in Effort to Educate Support and Inspire Kids With Diabetes 55174 4
... The immune response is actively turned on to target and ... it is just as important to turn the immune system ... fruit fly Drosophila has served as a good model for ... pathways and mechanisms. Recent work shows that the flys immune ...
... worlds first global inventory of farm animals showing many ... risk of extinction, scientists from the Consultative Group on ... establishment of genebanks to conserve the sperm and ovaries ... survival. , An over-reliance on just a few ...
... in This Edition:, , Fingerprinting fake coffee , Nanomagnetic ... carbon nanotubes show big germ-fighting potential , Toward improved drug-delivery: ... enhancement drugs show promise but face growing scrutiny , , , ... The Weekly ACS Podcast , ACS President Catherine ...
Other Biology News:Report: African, Asian, Latin American farm animals face extinction 2Report: African, Asian, Latin American farm animals face extinction 3Report: African, Asian, Latin American farm animals face extinction 4American Chemical Society's Weekly Presspac -- Aug. 29, 2007 2American Chemical Society's Weekly Presspac -- Aug. 29, 2007 3American Chemical Society's Weekly Presspac -- Aug. 29, 2007 4American Chemical Society's Weekly Presspac -- Aug. 29, 2007 5American Chemical Society's Weekly Presspac -- Aug. 29, 2007 6American Chemical Society's Weekly Presspac -- Aug. 29, 2007 7American Chemical Society's Weekly Presspac -- Aug. 29, 2007 8
p-Raf-1 (Ser 338/Tyr 341)-R...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Request Info...
Biology Products: